BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Citi maintains buy on Aurobindo Pharma
Citi has maintained buy on Aurobindo Pharma for target of Rs 1,050/share. It says Aurobindo started FY17 in same way as FY16 and full upside in earnings will come in next few quarters. Citi expects earnings growth to remain robust and street underestimates rising relevance of Aurobindo.